BioM?rieux (OTCMKTS:BMXMF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.
According to Zacks, “bioMérieux S.A. designs, develops, manufactures and markets systems in the field of vitro diagnostics. The company provides diagnostic solutions which determine the source of disease and contamination. It also offers solutions for managing infectious diseases, cancers and cardiovascular diseases in clinical applications. The company provides solutions for the enumeration of microbial flora, detection of specific pathogenic bacteria, monitoring of air and surface quality and sterility testing for the agri-food, cosmetics and pharmaceutical industries. bioMérieux S.A. is based in Marcy L Etoile, France. “
Shares of BioM?rieux stock opened at $78.95 on Thursday. The company has a quick ratio of 1.18, a current ratio of 1.82 and a debt-to-equity ratio of 0.23. BioM?rieux has a 1-year low of $78.00 and a 1-year high of $248.00.
BioM?rieux Company Profile
bioMérieux SA provides in vitro diagnostics solutions that determine the source of disease and contamination to enhance patient health and consumer safety worldwide. The company offers reagents, instruments, software, and services for diagnosing infectious diseases, healthcare-associated infections, antimicrobial resistance, sepsis, acquired immunodeficiency syndrome, hepatitis, acute care and cardiovascular emergencies, and cancer; and for detecting microorganisms in agri-food, pharmaceutical, biotechnology, and cosmetic products.
Receive News & Ratings for BioM?rieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioM?rieux and related companies with MarketBeat.com's FREE daily email newsletter.